On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
This COVID-19 roundup includes coverage of the latest and final COVID-19 treatment guidelines by the NIH, the effectiveness of the COVID-19 vaccine in preventing pediatric long COVID, the spring 2024...
Researchers developed a retrospective cohort study to examine the reoperation rates and health care costs associated with reoperation for patients who underwent breast-conserving surgery.
The CDC updated its guidance due to the United States seeing fewer hospitalizations associated with COVID-19 and because there are numerous tools to combat influenza, COVID-19, and respiratory syncytial...
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
Researchers examined the characteristics and trends related to the increased mortality rates associated with overdose in pregnant and postpartum women.
The CDC reported more than 200,000 cases of syphilis in 2022, a 17% increase compared with the previous year. In response, the CDC provided new recommendations for testing syphilis in the laboratory.
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
Using data from the Centers for Medicare & Medicaid Services Chronic Conditions Warehouse database, researchers set out to estimate the risk of gout following recombinant zoster vaccination among adults...
